![]() ![]() A possible explanation for the higher susceptibility observed for mumps might lie in the Rubini strain's low efficacy. The incidence of measles has enabled the National Measles Elimination Plan to be implemented by which the elimination of congenital rubella syndrome could now be initiated. In the case of mumps, this proved the lowest in the 2-5 year age group (76.7%) and in those autonomous regions in which only the Rubini strain had been administered. The total numbers of cases of each infection across 17 US Immigration and Customs Enforcement (ICE) detention centers that reported cases are shown for influenza. Immunity was the lowest in the 6-9 year age group for measles (90.8%) and in males aged between 15 and 24 years for rubella (86 and 89.8%, respectively). Data on International Classification of Diseases diagnosis for influenza, varicella, and mumps were obtained from January 1, 2017, to March 22, 2020, and plotted by date of diagnosis. Estimated vaccination coverage was 96% for children aged 2-5 years vaccine efficacies were 96.7% for measles, 97.2% for rubella and 79.3% for mumps. IgG antibodies were detected by an enzyme-linked immunosorbent assay. ![]() The sample was stratified by age and rural/ urban environment and informed consent obtained to take blood specimens from subjects attending blood-extraction centres. A population-based cross-sectional study was then conducted, covering the population aged 2-39 years, residing in Spain (excluding Catalonia). No data were available to assess the safety of the S79 strain. A seroepidemiological survey was undertaken to estimate the frequency of susceptible individuals by age and environment and vaccination coverage and efficacy of the vaccines administered. Extract from report of GACVS meeting of 29-30 November 2006, published in the WHO Weekly. Reported disease incidence was less than one case per 100,000 people for measles and rubella, and 23 cases per 100,000 people for mumps. In Spain, measles, mumps and rubella vaccination was introduced in 1981, with one dose at the age of 15 months and another at the age of 11 years being administered since 1995.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |